Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Stefanie, Zschäbitz"'
Autor:
Stefanie Zschäbitz, Nadine Biernath, Thomas Hilser, Alexander Höllein, Friedemann Zengerling, Jozefina Cascucelli, Pia Paffenholz, Daniel Seidl, Christoph Lutz, Katrin Schlack, Dorothea Kingreen, Niklas Klümper, Philipp Ivanyi, Gunhild von Amsberg, Hendrik Heers, Florian Roghmann, Robert L. Tauber, Richard Cathomas, Luisa Hofer, Günter Niegisch, Melanie Klee, Roland Ehrenberg, Andreas Hassler, Boris A. Hadaschik, Viktor Grünwald, Christopher Darr
Publikováno v:
European Urology Open Science, Vol 53, Iss , Pp 31-37 (2023)
Background: Treatment options for patients with urothelial cancer (UC) refractory to platinum and immunotherapy are limited and survival is short. Enfortumab vedotin (EV) is a monoclonal anti-NECTIN4 antibody conjugated to monomethyl auristatin. It w
Externí odkaz:
https://doaj.org/article/bd7cfc5ca9a44412a57048e564c5b88c
Autor:
Maximilian Erlmeier, Marie Mikuteit, Stefanie Zschäbitz, Michael Autenrieth, Wilko Weichert, Arndt Hartmann, Sandra Steffens, Franziska Erlmeier
Publikováno v:
BMC Urology, Vol 23, Iss 1, Pp 1-6 (2023)
Abstract Background The prognostic value of Hepatocyte growth factor (HGF) in non-clear cell renal cell carcinoma (RCC) is still unclear. The aim of this study is to evaluate the prognostic impact of HGF expression in a large cohort of chromophobe RC
Externí odkaz:
https://doaj.org/article/306b2fb9b3df4d509ccb2bcb9a804d73
Autor:
Philipp Reimold, Georgi Tosev, Adam Kaczorowski, Jana Friedhoff, Constantin Schwab, Viktoria Schütz, Magdalena Görtz, Niklas Panzer, Martina Heller, Cem Aksoy, Ruth Himmelsbach, Thomas Walle, Stefanie Zschäbitz, Dirk Jäger, Anette Duensing, Albrecht Stenzinger, Markus Hohenfellner, Stefan Duensing
Publikováno v:
Diagnostics, Vol 14, Iss 7, p 741 (2024)
Background: Renal cell carcinoma (RCC) is among the most lethal urologic malignancies once metastatic. Current treatment approaches for metastatic RCC (mRCC) involve immune checkpoint inhibitors (ICIs) that target the PD-L1/PD-1 axis. High PD-L1 expr
Externí odkaz:
https://doaj.org/article/024657d17a2c4da0b88ebf9657dd40fd
Autor:
Stefanie Zschäbitz, Marie Mikuteit, Christine Stöhr, Edwin Herrmann, Iris Polifka, Abbas Agaimy, Lutz Trojan, Philipp Ströbel, Frank Becker, Christian Wülfing, Peter Barth, Michael Stöckle, Michael Staehler, Christian Stief, Axel Haferkamp, Markus Hohenfellner, Stefan Duensing, Stephan Macher-Göppinger, Bernd Wullich, Joachim Noldus, Walburgis Brenner, Frederik C. Roos, Bernhard Walter, Wolfgang Otto, Maximilian Burger, Andres Jan Schrader, Arndt Hartmann, Franziska Erlmeier, Sandra Steffens
Publikováno v:
Discover Oncology, Vol 13, Iss 1, Pp 1-12 (2022)
Abstract Background Nectin-4 contributes to tumor proliferation, lymphangiogenesis and angiogenesis in malignant tumors and is an emerging target in tumor therapy. In renal cell carcinoma (RCC) VEGF-directed tyrosine kinase inhibitors and checkpoint
Externí odkaz:
https://doaj.org/article/f48c4647fe714704ac7639eb9dc60db9
Autor:
Jun Li, Stefanie Zschäbitz, Daniel P Petrylak, Margitta Retz, Prabhu Bhagavatheeswaran, Marc-Oliver Grimm, Jose Perez-Gracia, Gwenaelle Gravis, Karim Fizazi, Jeffrey C Goh, Mauricio Burotto, Daniel Castellano, Fred Saad, Andrew J Armstrong, HAKIM MAHAMMEDI, Russell K Pachynski, Louis Lacombe, Diogo Assed Bastos, Steven L McCune, Juan Carlos Vázquez Limón, Edmond M Kwan, Aude Fléchon, David R Shaffer, Neha P Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Andrea Loehr
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
Background CheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and A2 of CheckMate 9K
Externí odkaz:
https://doaj.org/article/47bed5baf90f4a54860bcc0aa14ca352
Autor:
Klaus-Peter Dieckmann, Tomas Pokrivcak, Lajos Geczi, David Niehaus, Inken Dralle-Filiz, Cord Matthies, Tamas Dienes, Stefanie Zschäbitz, Pia Paffenholz, Tanja Gschliesser, Renate Pichler, Michal Mego, Pia Bader, Friedemann Zengerling, Julia Heinzelbecker, Philipp Krausewitz, Susanne Krege, Gaetano Aurilio, Cem Aksoy, Marcus Hentrich, Christoph Seidel, Péter Törzsök, Tim Nestler, Matthaeus Majewski, Andreas Hiester, Tomas Buchler, Sonia Vallet, Hana Studentova, Sandra Schönburg, Dora Niedersüß-Beke, Julia Ring, Emanuela Trenti, Axel Heidenreich, Christian Wülfing, Hendrik Isbarn, Uwe Pichlmeier, Martin Pichler
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Introduction: Clinical stage 1 (CS1) nonseminomatous (NS) germ cell tumors involve a 30% probability of relapse upon surveillance. Adjuvant chemotherapy with one course of bleomycin, etoposide, and cisplatin (1xBEP) can reduce this risk to pT2 was si
Externí odkaz:
https://doaj.org/article/6fb1f473ab9e4ce38bbec32affcc8d33
Autor:
Hans-Christoph Friederich, Georg Martin Haag, Thomas Walle, Stefanie Zschäbitz, Imad Maatouk, Christina Sauer, Simeon Sauer, Senta Kiermeier
Publikováno v:
BMJ Open, Vol 11, Iss 7 (2021)
Introduction Immune checkpoint therapy (ICT) is associated with a distinct pattern of immune-related adverse events (irAEs) caused by inadvertently redirecting immune responses to healthy tissues. IrAEs can occur at any time; however, in most cases,
Externí odkaz:
https://doaj.org/article/980f2d699e7345a58ec6eee34d411baa
Autor:
Till Johannes Bugaj, Imad Maatouk, Tobias Hanslmeier, Stefanie Zschäbitz, Johannes Huber, Charlotte Flock, Hans-Christoph Friederich, Andreas Ihrig
Publikováno v:
World Journal of Urology. 41:1041-1046
Autor:
Jana, Friedhoff, Felix, Schneider, Christina, Jurcic, Volker, Endris, Martina, Kirchner, Angela, Sun, Iulia, Bolnavu, Laura, Pohl, Miriam, Teroerde, Maximilian, Kippenberger, Constantin, Schwab, Adam, Kaczorowski, Stefanie, Zschäbitz, Dirk, Jäger, Markus, Hohenfellner, Albrecht, Stenzinger, Anette, Duensing, Stefan, Duensing
Publikováno v:
Cancer Immunology, Immunotherapy. 72:1603-1618
Clear cell renal cell carcinoma (ccRCC) is an immunologically vulnerable tumor entity, and immune checkpoint inhibitors are now widely used to treat patients with advanced disease. Whether and to what extent immune responses in ccRCC are shaped by ge
Autor:
Sebastian Schölch, Benedikt Brors, Albrecht Stenzinger, Ursula Ehmer, Ulrich-Frank Pape, Christoph Springfeld, Dirk Jäger, Felix J Hüttner, Andreas Mock, Christoph E Heilig, Simon Kreutzfeldt, Daniel Huebschmann, Christoph Heining, Evelin Schröck, Richard Schlenk, Hanno Glimm, Stefan Fröhling, Peter Horak, Leonidas Apostolidis, Marinela Augustin, Daniela Aust, Irfan Ahmed Bhatti, Johannes Bloehdorn, Cornelia Brendel, Christian Britschgi, Jan Braess, Stefan Burdach, Elena Busch, Jozefina Casuscelli, Alexander Desuki, Thomas Deutsch, Mareike Dietrich, Thomas J Ettrich, Johanna Falkenhorst, Tanja Fehm, Anne Flörcken, Andrea Forschner, Stefan Fuxius, Maria Gonzales-Carmona, Frank Griesinger, Sabine Grill, Stefan Gröschel, Georg Martin Haag, Ulrich Haag, Niels Halama, Holger Hebart, Nina Heidger, Barbara Hermes, Georg Hess, Simone Hettmer, Manuela Hoechstetter, Martin Hoffmann, Anna L Illert, Maximilian Jenzer, Bernd Kasper, Stefan Kasper-Virchow, Thomas Kindler, Ewa Koscielniak, Jan Krönke, Michael Kühn, Volker Kunzmann, Alois Lang, Jonas Leichsenring, Elisabeth Livingstone, Lucia Liotta, Kim Luley, Elisabeth Mack, Uwe M Martens, Klaus Metzeler, Jan Moritz Middeke, Lino Möhrmann, Roopa Jayarama-Naidu, Lukas Perkhofer, Arne Pfeufer, Constantin Pixberg, Michael Quante, Bernhard Rendenbach, Damian Rieke, Christian Rothermundt, Andre Norbert Sagerer, Martin Salzmann, Dieter Saur, Bastian Schilling, Jan Schleicher, Anke Schlenska-Lange, Thomas Schmidt, Sophia Schmitz, Rajiv Shah, Khalid Shoumariyeh, Alexander Siebenhüner, Martin Singh, Jens Siveke, Helen Starke, Sophia Strobel, Veronica Teleanu, Niklas Thon, Sebastian Wagner, Thomas Walle, Benedikt Westphalen, Bettina Whitlock, Eva Winkler, Naita Maren Wirsik, Lena Woydack, Angelika Zabel-du Bois, Stefanie Zschäbitz
Publikováno v:
ESMO Open, Vol 4, Iss 6 (2019)
Objective Measuring the success of molecularly guided therapies is a major challenge in precision oncology trials. A commonly used endpoint is an intra-patient progression-free survival (PFS) ratio, defined as the PFS interval associated with molecul
Externí odkaz:
https://doaj.org/article/0122f1ac148444cbaeb951db5af876a5